$Ocugen (OCGN.US)$ OCGN reprint The trend is gradually chang...
$Ocugen(OCGN.US$ OCGN replay
The trend is gradually changing. There was a large inflow of capital on Friday. The main increase was strong, and the bulls were weak. When the breakthrough broke out, it was as shown in the picture. The breakthrough cannot be stepped down. Look at 10-12
Strong support from below, fluctuations are being consolidated upward. For example, the pullback continues to throw high and suck low
The trend is gradually changing. There was a large inflow of capital on Friday. The main increase was strong, and the bulls were weak. When the breakthrough broke out, it was as shown in the picture. The breakthrough cannot be stepped down. Look at 10-12
Strong support from below, fluctuations are being consolidated upward. For example, the pullback continues to throw high and suck low
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Gobiss : Little White is asking for 8 now. Is it okay?
heracheongOP Gobiss: rows
9865977689 : What would be the support point for Oshimaiichi?
heracheongOP 9865977689: OCGN replay
The trend is gradually changing. A large amount of capital flowed in on Friday, the main increase was strong, and the bulls were weak. As shown in the illustration when a breakthrough broke out, the strong pressure was 8.442-8.67-8.76, and the breakout couldn't be stepped back. Look at 10-12
Strong support from below, and upward shocks are being sorted out.
Sustainable purchases below 8.35
Support level 5.98-7.74-8.116
heracheongOP 9865977689: Make notes to yourself
heracheongOP heracheongOP: Strong support from below, and upward shocks are being sorted out.
Sustainable purchases below 8.35
Support level 5.98-7.74-8.116
9865977689 heracheongOP: They can all count to two decimal places. I'm satisfied
heracheongOP 9865977689:
voix : Super good news has arrived. ^_^
https://www.nih.gov/news-events/news-releases/adjuvant-developed-nih-funding-enhances-efficacy-indias-covid-19-vaccine